 Leonard Seibold
Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 37 | 2026 | 247 | 9.090 |
Why?
| | Intraocular Pressure | 48 | 2026 | 326 | 7.460 |
Why?
| | Glaucoma, Open-Angle | 20 | 2023 | 104 | 6.160 |
Why?
| | Trabeculectomy | 17 | 2026 | 75 | 5.090 |
Why?
| | Phacoemulsification | 14 | 2025 | 123 | 4.360 |
Why?
| | Glaucoma Drainage Implants | 11 | 2026 | 46 | 3.140 |
Why?
| | Cataract | 10 | 2023 | 212 | 2.630 |
Why?
| | Ocular Hypertension | 7 | 2022 | 67 | 2.460 |
Why?
| | Trabecular Meshwork | 8 | 2026 | 74 | 2.320 |
Why?
| | Tonometry, Ocular | 23 | 2025 | 103 | 2.080 |
Why?
| | Visual Acuity | 13 | 2025 | 491 | 1.900 |
Why?
| | Filtering Surgery | 7 | 2026 | 23 | 1.730 |
Why?
| | Ciliary Body | 3 | 2025 | 40 | 1.450 |
Why?
| | Pilocarpine | 2 | 2025 | 16 | 1.440 |
Why?
| | Laser Coagulation | 4 | 2025 | 79 | 1.440 |
Why?
| | Stents | 5 | 2026 | 557 | 1.300 |
Why?
| | Endoscopy | 3 | 2025 | 317 | 1.210 |
Why?
| | Glaucoma, Angle-Closure | 2 | 2020 | 23 | 1.180 |
Why?
| | Ophthalmology | 4 | 2023 | 116 | 1.020 |
Why?
| | Cataract Extraction | 5 | 2020 | 120 | 1.020 |
Why?
| | Laser Therapy | 3 | 2018 | 140 | 0.990 |
Why?
| | Ophthalmic Solutions | 6 | 2018 | 79 | 0.820 |
Why?
| | Antihypertensive Agents | 5 | 2017 | 512 | 0.770 |
Why?
| | Lens Implantation, Intraocular | 3 | 2018 | 80 | 0.760 |
Why?
| | Retinal Ganglion Cells | 3 | 2025 | 115 | 0.700 |
Why?
| | Nerve Fibers | 2 | 2012 | 105 | 0.670 |
Why?
| | Perception | 3 | 2021 | 376 | 0.660 |
Why?
| | Legislation, Drug | 1 | 2020 | 73 | 0.610 |
Why?
| | Tomography, Optical Coherence | 2 | 2012 | 270 | 0.600 |
Why?
| | Postoperative Period | 7 | 2025 | 351 | 0.590 |
Why?
| | Specialization | 1 | 2020 | 136 | 0.590 |
Why?
| | Burnout, Professional | 2 | 2025 | 483 | 0.580 |
Why?
| | Remote Sensing Technology | 1 | 2019 | 19 | 0.570 |
Why?
| | Retrospective Studies | 23 | 2025 | 17147 | 0.560 |
Why?
| | Medical Marijuana | 1 | 2020 | 122 | 0.550 |
Why?
| | Angiogenesis Inhibitors | 5 | 2020 | 238 | 0.540 |
Why?
| | Humans | 66 | 2026 | 144665 | 0.530 |
Why?
| | Aged, 80 and over | 14 | 2025 | 8283 | 0.520 |
Why?
| | Brimonidine Tartrate | 1 | 2017 | 10 | 0.510 |
Why?
| | Thiazines | 1 | 2017 | 13 | 0.510 |
Why?
| | Timolol | 1 | 2017 | 14 | 0.500 |
Why?
| | Marijuana Smoking | 1 | 2020 | 249 | 0.500 |
Why?
| | Aged | 21 | 2025 | 25955 | 0.500 |
Why?
| | Marijuana Use | 1 | 2020 | 212 | 0.490 |
Why?
| | Preservatives, Pharmaceutical | 2 | 2013 | 28 | 0.480 |
Why?
| | Treatment Outcome | 15 | 2026 | 11734 | 0.480 |
Why?
| | Prospective Studies | 11 | 2021 | 7994 | 0.480 |
Why?
| | Sulfonamides | 2 | 2017 | 579 | 0.470 |
Why?
| | Corneal Diseases | 1 | 2016 | 46 | 0.460 |
Why?
| | Endophthalmitis | 1 | 2016 | 46 | 0.460 |
Why?
| | Vision Disorders | 3 | 2025 | 179 | 0.440 |
Why?
| | Middle Aged | 22 | 2025 | 35968 | 0.440 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2024 | 189 | 0.440 |
Why?
| | Circadian Rhythm | 2 | 2023 | 510 | 0.430 |
Why?
| | Ocular Hypotension | 3 | 2022 | 10 | 0.410 |
Why?
| | Cloprostenol | 1 | 2013 | 13 | 0.400 |
Why?
| | Prosthesis Implantation | 4 | 2022 | 154 | 0.390 |
Why?
| | Physicians | 1 | 2022 | 949 | 0.390 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1505 | 0.380 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5414 | 0.380 |
Why?
| | Benzalkonium Compounds | 1 | 2012 | 15 | 0.370 |
Why?
| | Visual Fields | 2 | 2025 | 116 | 0.370 |
Why?
| | Male | 28 | 2025 | 72425 | 0.370 |
Why?
| | Drug Combinations | 3 | 2020 | 393 | 0.360 |
Why?
| | Female | 29 | 2025 | 78301 | 0.360 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.330 |
Why?
| | Wound Healing | 2 | 2012 | 352 | 0.320 |
Why?
| | Blood Pressure | 2 | 2017 | 1766 | 0.320 |
Why?
| | Stainless Steel | 1 | 2010 | 21 | 0.320 |
Why?
| | Optic Disk | 1 | 2010 | 53 | 0.310 |
Why?
| | Contact Lenses | 2 | 2020 | 13 | 0.300 |
Why?
| | Uveitis | 2 | 2022 | 149 | 0.300 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2201 | 0.290 |
Why?
| | Prednisolone | 2 | 2020 | 66 | 0.270 |
Why?
| | Adult | 17 | 2025 | 40486 | 0.270 |
Why?
| | Software | 1 | 2012 | 695 | 0.250 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.220 |
Why?
| | Reproducibility of Results | 4 | 2024 | 3414 | 0.220 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 14 | 0.220 |
Why?
| | Optometry | 1 | 2025 | 9 | 0.220 |
Why?
| | Optometrists | 1 | 2025 | 12 | 0.220 |
Why?
| | Visual Pathways | 1 | 2025 | 61 | 0.220 |
Why?
| | Optic Nerve Diseases | 1 | 2025 | 49 | 0.220 |
Why?
| | Alkylating Agents | 2 | 2016 | 24 | 0.210 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5869 | 0.210 |
Why?
| | Glaucoma, Neovascular | 2 | 2015 | 10 | 0.210 |
Why?
| | Postoperative Care | 2 | 2025 | 286 | 0.210 |
Why?
| | Glucocorticoids | 2 | 2020 | 528 | 0.200 |
Why?
| | Sleep | 2 | 2023 | 890 | 0.200 |
Why?
| | Macular Edema | 1 | 2023 | 49 | 0.190 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 80 | 0.180 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 6041 | 0.180 |
Why?
| | Communication Barriers | 1 | 2023 | 130 | 0.170 |
Why?
| | Heart Rate | 2 | 2017 | 853 | 0.170 |
Why?
| | Diabetic Retinopathy | 1 | 2023 | 199 | 0.170 |
Why?
| | Manometry | 1 | 2021 | 97 | 0.170 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.160 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 10 | 0.160 |
Why?
| | Gonioscopy | 1 | 2020 | 11 | 0.160 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 16 | 0.160 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.160 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 30 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2020 | 550 | 0.160 |
Why?
| | Amyloidosis | 1 | 2020 | 44 | 0.160 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2020 | 53 | 0.150 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 496 | 0.150 |
Why?
| | Language | 1 | 2023 | 323 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2023 | 318 | 0.150 |
Why?
| | Retinal Diseases | 1 | 2020 | 101 | 0.150 |
Why?
| | Eye Diseases | 1 | 2020 | 95 | 0.150 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 422 | 0.150 |
Why?
| | Intraoperative Complications | 1 | 2020 | 157 | 0.140 |
Why?
| | Mitomycin | 2 | 2016 | 32 | 0.140 |
Why?
| | Preoperative Period | 1 | 2019 | 149 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 2 | 2014 | 3887 | 0.140 |
Why?
| | United States | 5 | 2025 | 16018 | 0.140 |
Why?
| | Axial Length, Eye | 1 | 2018 | 16 | 0.140 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.140 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.140 |
Why?
| | Biosensing Techniques | 1 | 2020 | 140 | 0.140 |
Why?
| | Pseudophakia | 1 | 2018 | 21 | 0.140 |
Why?
| | Young Adult | 6 | 2025 | 14119 | 0.140 |
Why?
| | Refraction, Ocular | 1 | 2018 | 47 | 0.130 |
Why?
| | Uveitis, Anterior | 1 | 2018 | 27 | 0.130 |
Why?
| | Time Factors | 2 | 2019 | 7140 | 0.130 |
Why?
| | Intravitreal Injections | 4 | 2020 | 71 | 0.130 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 18 | 0.130 |
Why?
| | Equipment Design | 1 | 2018 | 527 | 0.120 |
Why?
| | Fluoroquinolones | 1 | 2016 | 45 | 0.120 |
Why?
| | Healthcare Disparities | 1 | 2023 | 736 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 743 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 380 | 0.110 |
Why?
| | Lasers, Semiconductor | 1 | 2015 | 11 | 0.110 |
Why?
| | Drug Packaging | 1 | 2015 | 41 | 0.110 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 108 | 0.110 |
Why?
| | Device Removal | 1 | 2016 | 142 | 0.110 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2014 | 12 | 0.100 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 28 | 0.100 |
Why?
| | Travoprost | 1 | 2013 | 13 | 0.100 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2014 | 90 | 0.100 |
Why?
| | Patient Preference | 1 | 2016 | 226 | 0.100 |
Why?
| | Antimetabolites | 1 | 2012 | 21 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 667 | 0.090 |
Why?
| | Anterior Chamber | 1 | 2012 | 26 | 0.090 |
Why?
| | Conjunctiva | 1 | 2012 | 52 | 0.090 |
Why?
| | Blister | 1 | 2012 | 39 | 0.090 |
Why?
| | Prostaglandins F | 1 | 2011 | 15 | 0.090 |
Why?
| | Quality of Life | 1 | 2024 | 3183 | 0.090 |
Why?
| | Adenoma | 1 | 2014 | 218 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 957 | 0.080 |
Why?
| | Medication Adherence | 1 | 2015 | 540 | 0.080 |
Why?
| | Equipment Safety | 1 | 2010 | 38 | 0.080 |
Why?
| | Electromagnetic Fields | 1 | 2010 | 37 | 0.080 |
Why?
| | Torque | 1 | 2010 | 81 | 0.080 |
Why?
| | Dexamethasone | 1 | 2012 | 366 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1044 | 0.080 |
Why?
| | Tissue Donors | 1 | 2012 | 413 | 0.070 |
Why?
| | Cell Survival | 1 | 2012 | 1092 | 0.070 |
Why?
| | Reference Values | 1 | 2010 | 794 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2573 | 0.070 |
Why?
| | Cohort Studies | 1 | 2019 | 5957 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 834 | 0.070 |
Why?
| | Adolescent | 4 | 2020 | 22405 | 0.060 |
Why?
| | Inflammation | 1 | 2018 | 2870 | 0.060 |
Why?
| | Administration, Topical | 2 | 2016 | 152 | 0.060 |
Why?
| | Geniculate Bodies | 1 | 2025 | 22 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1928 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2012 | 2489 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2012 | 4110 | 0.050 |
Why?
| | Sickness Impact Profile | 1 | 2024 | 62 | 0.050 |
Why?
| | Safety-net Providers | 1 | 2023 | 128 | 0.040 |
Why?
| | Rabbits | 2 | 2012 | 651 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2022 | 324 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2024 | 707 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 260 | 0.040 |
Why?
| | Histological Techniques | 1 | 2018 | 39 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2023 | 607 | 0.030 |
Why?
| | Postoperative Complications | 2 | 2021 | 2950 | 0.030 |
Why?
| | Prevalence | 1 | 2025 | 2839 | 0.030 |
Why?
| | Risk Assessment | 2 | 2020 | 3729 | 0.030 |
Why?
| | Reoperation | 1 | 2020 | 624 | 0.030 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 170 | 0.030 |
Why?
| | Microscopy | 1 | 2018 | 148 | 0.030 |
Why?
| | Perioperative Care | 1 | 2019 | 231 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 547 | 0.030 |
Why?
| | Medication Errors | 1 | 2015 | 82 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 288 | 0.030 |
Why?
| | Iris | 1 | 2013 | 23 | 0.020 |
Why?
| | Pilot Projects | 1 | 2018 | 1886 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2847 | 0.020 |
Why?
| | Goblet Cells | 1 | 2012 | 22 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 503 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1700 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 284 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4312 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 184 | 0.020 |
Why?
| | Collagen | 1 | 2012 | 450 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2019 | 0.020 |
Why?
| | Animals | 3 | 2012 | 37948 | 0.010 |
Why?
| | Child | 1 | 2020 | 22599 | 0.010 |
Why?
|
|
Seibold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|